Graphite Bio (NASDAQ:GRPH – Get Rating) and Cellectis (NASDAQ:CLLS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Graphite Bio and Cellectis’ […]
Cellectis (NASDAQ:CLLS – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis […]
Analysts expect that Cellectis S.A. (NASDAQ:CLLS – Get Rating) will post $22.85 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cellectis’ earnings. The lowest sales estimate is $13.50 million and the highest is $32.20 million. Cellectis posted sales of $27.97 million in the same quarter last year, […]
StockNews.com upgraded shares of Cellectis (NASDAQ:CLLS – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Friday morning. CLLS has been the topic of several other research reports. JMP Securities reissued a buy rating on shares of Cellectis in a report on Tuesday, December 14th. Zacks […]
Cellectis S.A. (NASDAQ:CLLS – Get Rating) – Stock analysts at William Blair issued their Q1 2023 earnings per share estimates for shares of Cellectis in a report issued on Monday, March 7th. William Blair analyst R. Prasad expects that the biotechnology company will earn ($0.91) per share for the quarter. William Blair also issued estimates […]